1.08
+0(+0.00%)
Currency In USD
| Previous Close | 1.08 |
| Open | 1.1 |
| Day High | 1.1 |
| Day Low | 1.07 |
| 52-Week High | 2.24 |
| 52-Week Low | 0.77 |
| Volume | 631,273 |
| Average Volume | 804,879 |
| Market Cap | 90.43M |
| PE | -3.09 |
| EPS | -0.35 |
| Moving Average 50 Days | 1.18 |
| Moving Average 200 Days | 1.21 |
| Change | 0 |
If you invested $1000 in Cardiol Therapeutics Inc. (CRDL) since IPO date, it would be worth $288.65 as of September 29, 2025 at a share price of $1.08. Whereas If you bought $1000 worth of Cardiol Therapeutics Inc. (CRDL) shares 5 years ago, it would be worth $463.14 as of September 29, 2025 at a share price of $1.08.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference
Newsfile
Aug 11, 2025 11:27 AM GMT
Toronto, Ontario--(Newsfile Corp. - August 11, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for t
Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis
Newsfile
Aug 06, 2025 11:27 AM GMT
Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) favouring CardiolRx™ over placebo.Reduction in ECV was associated with improvements across multiple pre-specified cardiac mag
Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis
Newsfile
Jul 22, 2025 11:27 AM GMT
ARCHER is designed to assess the impact of CardiolRx™ on cardiac magnetic resonance imaging parameters that measure heart dysfunction and edema/fibrosis-key measurements used to predict prognosis in myocarditis patients.Acute myocarditis is a potenti